| Bioactivity | NNRTIs-IN-1 is a potent non-nucleoside reverse transcriptase inhibitor featuring significantly anti-resistance efficacy. NNRTIs-IN-1 inhibits the wild-type HIV-1 and five mutant strains with EC50s in the nanomolar range. NNRTIs-IN-1 displays favorable pharmacokinetic properties[1]. |
| Invitro | NNRTIs-IN-1 (compound 8r) 抑制野生型 HIV-1 (EC50=2.3 nM) 和五种突变株：K103N (EC50=8 nM)，E138K (EC50=6 nM)，L100I (EC50=13 nM)，Y181C (EC50=29 nM) 和 Y188L (EC50=52 nM)[1]。NNRTIs-IN-1 对 CYP1A2，CYP2D6，CYP3A4-T 和 CYP3A4-M 没有明显的抑制作用，IC50 值超过 50 μM，对 RPV 敏感的 CYP2C9 和 CYP2C19 亚型表现出极弱的活性 (IC50=18.5 和 23.6 μM)[1]。NNRTIs-IN-1 对 hERG 表现出非常弱的抑制作用 (IC50>40 μM)[1]。 |
| In Vivo | NNRTIs-IN-1 (compound 8r) (1 mg/kg; i.v.) 的半衰期为 3.66 h，平均停留时间 (MRT) 为 3.75 h，最大浓度 (Cmax) 高达 431 ng/mL[1]。NNRTIs-IN-1 (1 mg/kg; i.v.) 的半衰期为 5.18 h，MRT 为 5.21 h，Cmax 为 616 ng/mL，口服生物利用度 (F) 为 31.19%[1]。NNRTIs-IN-1 (p.o.) 在 2 g/kg 的剂量下具有良好的耐受性[1]。 |
| Name | NNRTIs-IN-1 |
| Formula | C28H22N6O3 |
| Molar Mass | 490.51 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sang YL, et, al. Fragment Hopping-Based Design of Novel Biphenyl-DAPY Derivatives as Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Significantly Improved Anti-Resistance Efficacy. J Med Chem. 2023 Apr 13;66(7):4755-4767. |